V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Arcellx Executive Compensation (FY24)

ACLX · Executive and director compensation, fiscal 2022 to 2024
Data as of September 7, 2026Latest filing (8-K): May 28, 2025
132 figures on this page: 130 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
Rami Elghandour, President, Chief Executive Officer and Chairman, received $21,402,668 in total compensation for fiscal 2024, and compared with the $24,964,306 reported for fiscal 2023, Elghandour's total was 14.3% lower. For fiscal 2024, the say-on-pay proposal drew 80.8% support at the meeting held May 28, 2025. Companies named in the disclosed peer group include Akero Therapeutics, Inc., Allogene Therapeutics, Inc., Arcus Biosciences, Inc., Arrowhead Pharmaceuticals, Inc. and Arvinas, Inc., among others. The company reported 3 named executive officers for fiscal 2024.
Chief executive, fiscal 2024
◇
Rami Elghandour
Latest say-on-pay support
=
May 28, 2025
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Rami Elghandour: $24,964,306 → $21,402,668 (14.3% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Arcellx's chief executive and what were they paid?
Rami Elghandour, President, Chief Executive Officer and Chairman, received $21,402,668 in total compensation for fiscal 2024. Compared with the $24,964,306 reported for fiscal 2023, Elghandour's total was 14.3% lower.
What was Arcellx's say-on-pay result?
For fiscal 2024, the say-on-pay proposal drew 80.8% support at the meeting held May 28, 2025.
Which companies are in Arcellx's peer group?
Companies named in the disclosed peer group include Akero Therapeutics, Inc., Allogene Therapeutics, Inc., Arcus Biosciences, Inc., Arrowhead Pharmaceuticals, Inc. and Arvinas, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Rami Elghandour
President, Chief Executive Officer and Chairman
◇◇◇◇——◇— not reconciled
Christopher Heery
Chief Medical Officer
◇◇◇◇——◇◇
Michelle Gilson
Chief Financial Officer
◇◇◇◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Rami Elghandour
President, Chief Executive Officer and Chairman
◇◇◇◇——◇◇
Christopher Heery
Chief Medical Officer
◇◇◇◇——◇◇
Michelle Gilson
Chief Financial Officer
◇◇◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Rami Elghandour
President, Chief Executive Officer and Chairman
◇◇◇◇——◇◇
Michelle Gilson
Chief Financial Officer
◇◇◇◇——◇◇
Christopher Heery
Chief Medical Officer
◇◇◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Christopher HeeryOPTION◇——◇—◇◇
Christopher HeeryRSU◇——◇——◇
Michelle GilsonRSU◇——◇——◇
Michelle GilsonOPTION◇——◇—◇◇
Rami ElghandourRSU◇——◇——◇
Rami ElghandourOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Rami ElghandourRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Michelle GilsonRSU◇◇——
RSU◇◇——
RSU◇◇——
Christopher HeeryRSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Lubner
◇—◇———◇
Ali Behbahani
◇—◇———◇
Jill Carroll
◇—◇———◇
Derek Yoon
◇—◇———◇
Kavita Patel
◇—◇———◇
Olivia Ware
◇—◇———◇
Kristin Myers, Rami Elghandour and Andrew Galligan served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • Akero Therapeutics, Inc. AKRO
  • Allogene Therapeutics, Inc. ALLO
  • Arcus Biosciences, Inc. RCUS
  • Arrowhead Pharmaceuticals, Inc. ARWR
  • Arvinas, Inc. ARVN
  • Beam Therapeutics, Inc. BEAM
  • Cerevel Therapeutics Holdings, Inc. CERE
  • CRISPR Therapeutics, AG CRSP
  • Denali Therapeutics, Inc. DNLI
  • Intellia Therapeutics, Inc. NTLA
  • Lyell Immunopharma, Inc. LYEL
  • Morphic Holding, Inc. MORF
  • Pliant Therapeutics, Inc. PLRX
  • Relay Therapeutics, Inc. RLAY
  • Replimune Group, Inc. REPL
  • Revolution Medicines, Inc. RVMD
  • Vaxcyte, Inc. PCVX
  • Zentalis Pharmaceuticals, Inc. ZNTL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024May 28, 2025=◇◇◇
2023May 24, 2024=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Arcellx files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Arcellx disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Arcellx sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Arcellx's disclosed peer group is defensible, who names Arcellx back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
132 figures on this page: 130 cited to the filing that reported them, 2 calculated from figures it prints.
130 cited to the filing
2 calculated from the filing

Documents cited

  1. 0001193125-25-129522
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-25-084363
    Director Compensation · Director Compensation for Fiscal 2024 · EXECUTIVE COMPENSATION · Grants of Plan-Based Awards in 2024 · and 2 more sections
  3. 0001193125-24-148245
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001193125-24-093275
    Summary Compensation Table
  5. 0000950170-23-015761
    Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Arcellx executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/ACLX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Arcellx and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Arcellx discloses

The companies named in ACLX's own disclosed peer group.

Allogene Therapeutics, Inc.Arcus Biosciences, Inc.Arrowhead Pharmaceuticals, Inc.Arvinas, Inc.Beam Therapeutics, Inc.CRISPR Therapeutics, AGDenali Therapeutics, Inc.Lyell Immunopharma, Inc.Pliant Therapeutics, Inc.Relay Therapeutics, Inc.Replimune Group, Inc.Vaxcyte, Inc.Zentalis Pharmaceuticals, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy